• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Remote Care Technology Top Pick for ’23 Impact | Managed Healthcare Executive® State of the Industry Survey

MHE PublicationMHE January 2023
Volume 33
Issue 1

In the political and policy arena, respondents see implementation of the Inflation Recovery Act as having a major effect this year.

Healthcare technology is teeming with possibilities for improving the cost and delivery of healthcare. Precision medicine, artificial intelligence, prescription digital therapeutics — they are all being talked about as powerful waves that will shape the future contours of U.S. healthcare.

But as far as having an effect this year, remote are technologies was the top pick among the respondents to the Managed Healthcare Executive® annual State of the Industry survey. A solid majority — 56% — of the approximately 450 respondents to the survey indicated that remote care technology would be among the healthcare technology developments to have the biggest effect on the cost and delivery of healthcare in 2023.

One-third (33%) of the respondents picked interoperability. A similar proportion (32%) picked prescription digital therapeutics. The respondents were instructed to pick more than one of the choices, which also included gene therapy,precision medicine and artificial intelligence

In the policy and political arena, implementation of the healthcare provisions of the Inflation Recovery Act was the top pick for making a splash this year: 54% of the respondents picked it in response a question which policy and political developments will have the biggest effect this year. Perhaps the most important provision of the law is the one that empowers CMS to negotiate drug prices. According to a timeline that CMS issued last week, CMS will publish a list of the first 10 drugs for which it will negotiate a price on Sept. 1, 2023, but it won’t be until 2026 that the negotiated prices will go into effect.

A little more than one-third (35%) respondents picked the end of the COVID-19 public health emergency as having a large effect this year and less than one-third (31%) picked the end of continuous Medicaid enrollment.

The survey was conducted online in November and early December. Medical Economics® assisted with its distribution,

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.